{"id":"placebo-matched-to-iva","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo serves as a comparator arm in clinical trials to establish the efficacy of the active investigational drug (IVA) by controlling for non-specific effects, natural disease progression, and patient expectations. It contains no active pharmaceutical ingredient and produces therapeutic effects only through psychological mechanisms such as expectation and conditioning.","oneSentence":"Placebo is an inert control substance with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:54.186Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control comparator in phase 3 clinical trial for IVA (specific indication unknown)"}]},"trialDetails":[{"nctId":"NCT04849728","phase":"PHASE3","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventiva Pharma","startDate":"2021-08-19","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":1000},{"nctId":"NCT06154447","phase":"PHASE1","title":"Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-12-12","conditions":"Cystic Fibrosis","enrollment":255},{"nctId":"NCT05386550","phase":"PHASE3","title":"Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-10-06","conditions":"Head and Neck Cancer","enrollment":166},{"nctId":"NCT02070744","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2014-03","conditions":"Cystic Fibrosis","enrollment":40},{"nctId":"NCT05033080","phase":"PHASE3","title":"A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-09-14","conditions":"Cystic Fibrosis","enrollment":435},{"nctId":"NCT05274269","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-05-09","conditions":"Cystic Fibrosis","enrollment":307},{"nctId":"NCT05076149","phase":"PHASE3","title":"A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-27","conditions":"Cystic Fibrosis","enrollment":597},{"nctId":"NCT03912233","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-04-30","conditions":"Cystic Fibrosis","enrollment":87},{"nctId":"NCT03625466","phase":"PHASE2","title":"A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-08-10","conditions":"Cystic Fibrosis","enrollment":51},{"nctId":"NCT04353817","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-06-19","conditions":"Cystic Fibrosis","enrollment":121},{"nctId":"NCT03768089","phase":"PHASE1, PHASE2","title":"Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-03-20","conditions":"Cystic Fibrosis","enrollment":115},{"nctId":"NCT03911713","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-04-17","conditions":"Cystic Fibrosis","enrollment":77},{"nctId":"NCT03227471","phase":"PHASE1, PHASE2","title":"A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-01-23","conditions":"Cystic Fibrosis","enrollment":225},{"nctId":"NCT02508207","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-02","conditions":"Cystic Fibrosis","enrollment":34},{"nctId":"NCT03224351","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-08-08","conditions":"Cystic Fibrosis","enrollment":124},{"nctId":"NCT02951195","phase":"PHASE2","title":"A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-11","conditions":"Cystic Fibrosis","enrollment":80},{"nctId":"NCT02951182","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-10","conditions":"Cystic Fibrosis","enrollment":74},{"nctId":"NCT03525444","phase":"PHASE3","title":"A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-06-15","conditions":"Cystic Fibrosis","enrollment":405},{"nctId":"NCT03447249","phase":"PHASE3","title":"A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-03-07","conditions":"Cystic Fibrosis","enrollment":385},{"nctId":"NCT03068312","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-07-18","conditions":"Cystic Fibrosis","enrollment":38},{"nctId":"NCT03559062","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-05-17","conditions":"Cystic Fibrosis","enrollment":67},{"nctId":"NCT03525548","phase":"PHASE3","title":"A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-08-03","conditions":"Cystic Fibrosis","enrollment":113},{"nctId":"NCT02730208","phase":"PHASE2","title":"A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-09","conditions":"Cystic Fibrosis","enrollment":41},{"nctId":"NCT03460990","phase":"PHASE3","title":"A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-05-01","conditions":"Cystic Fibrosis","enrollment":116},{"nctId":"NCT03150719","phase":"PHASE3","title":"A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-05-24","conditions":"Cystic Fibrosis","enrollment":98},{"nctId":"NCT02875366","phase":"PHASE4","title":"A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-09","conditions":"Cystic Fibrosis","enrollment":70},{"nctId":"NCT02392234","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-03","conditions":"Cystic Fibrosis","enrollment":248},{"nctId":"NCT02347657","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-01","conditions":"Cystic Fibrosis","enrollment":510},{"nctId":"NCT02516410","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":168},{"nctId":"NCT03486236","phase":"PHASE1","title":"A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-07-20","conditions":"Cystic Fibrosis","enrollment":16},{"nctId":"NCT02514473","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-07","conditions":"Cystic Fibrosis","enrollment":206},{"nctId":"NCT03029455","phase":"PHASE1","title":"A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-11","conditions":"Cystic Fibrosis","enrollment":163},{"nctId":"NCT01931839","phase":"PHASE3","title":"A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-10","conditions":"Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation","enrollment":1164},{"nctId":"NCT00908414","phase":"PHASE1","title":"PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.","status":"WITHDRAWN","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-05","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT01807949","phase":"PHASE3","title":"A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-04","conditions":"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation","enrollment":563},{"nctId":"NCT01225211","phase":"PHASE2","title":"Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2010-10","conditions":"Cystic Fibrosis","enrollment":312},{"nctId":"NCT01807923","phase":"PHASE3","title":"A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-05","conditions":"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation","enrollment":559},{"nctId":"NCT00538850","phase":"PHASE3","title":"Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2007-10","conditions":"Cancer","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (matched to IVA)","genericName":"Placebo (matched to IVA)","companyName":"Vertex Pharmaceuticals Incorporated","companyId":"vertex-pharmaceuticals-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo is an inert control substance with no active pharmacological mechanism. Used for Control comparator in phase 3 clinical trial for IVA (specific indication unknown).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}